|
67 |
[2026.10.02] (주)큐브바이오, SEC Form F-4 효력발생…Nasdaq ‘Global Market’상장 예정
|
2026-10-01 |
445 |
|
66 |
[2025.08.25] CUBEBIO Co., Ltd. enters MENA·EU in earnest, signed distribution and investment agreement
|
2025-08-25 |
5,682 |
|
65 |
[2025.06.23] CUBEBIO Co., Ltd. Collaborates with Korean Medical Institutions and Global Reinsurer on Pancreatic Cancer Screening Service Through Four-Party Agreement
|
2025-06-23 |
5,982 |
|
64 |
[2025.04.14] CUBEBIO Co., Ltd. Secures 4.6 Trillion KRW Export Deal with India for Urine-Based Cancer Screening Products
|
2025-04-15 |
6,335 |
|
63 |
[2024.09.02] CUEBIO Signs the Merger Agreement for the Nasdaq SPAC
|
2024-09-02 |
13,339 |
|
62 |
[2024.06.26] "Diagnosing cancer in 5 minutes using urine," interview with Jaemyeong Kim, the Vice Chairman of CUBEBIO
|
2024-07-22 |
10,997 |
|
61 |
[2024.05.03] CUBEBIO Co., Ltd. signed term sheets worth KRW 850 billion with Mountain Crest Acquisition Corp. V, a NASDAQ-listed SPAC company in the U.S.
|
2024-05-03 |
12,304 |
|
60 |
[2024.04.01] CUBEBIO Co., Ltd. signs a USD 14.8Mn-worth exclusive distribution agreement for cancer screening products with the Taiwanese pharmaceutical group Taiwan Biotech Co., Ltd.
|
2024-04-01 |
9,998 |
|
59 |
[2024.01.22] CUBEBIO Co., Ltd. signed NASDAQ SPAC listing agreement
|
2024-01-22 |
23,643 |
|
58 |
[2023.09.21] CUBEBIO Co., Ltd. Attracts Investment of $46.7Mn through Technology Verification .. One step forward for US Market entry
|
2023-09-21 |
28,541 |
